Case Reports
Share your love
First patient dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111
(Image Credit: AdobeStock) The first patient has been dosed in Qlaris Bio’s Phase II Nightingale clinical trial for QLS-111 in patients with normal tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s…
OCT changes with low-level red light therapy for myopia in children
(Image credit: AdobeStock/Microgen) Zhehuan Zhang, MD, and colleagues from the Department of Ophthalmology, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, emphasized the importance of patients undergoing routine optical coherence tomography (OCT) scans during repeated low-level red-light (RLRL)…
The potential of AI in retina with Daniela Ferrara
This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…
Opthea parts with CEO, lays off over 80% of company
(Image Credit: AdobeStock/Andrii Yalanskyi) Opthea has released a corporate update following its settlement of the Development Funding Agreement (“DFA”) with the 2 investors under the DFA.1 The company previously provided an update in April 20252 stating its intention to lay…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…
Study establishes reference data set for geographic atrophy lesion progression
(Image Credit: AdobeStock/tadamichi) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science &…
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
An unusual encounter in ophthalmology: Fronto-Ethemoido-Orbital Osteoma with the art of precise referral and management of PEEK implant infection- A rare case report – ScienceDirect.com
An unusual encounter in ophthalmology: Fronto-Ethemoido-Orbital Osteoma with the art of precise referral and management of PEEK implant infection- A rare case report ScienceDirect.com Source: Author: | Date: 2025-01-17 21:47:00 Source: Author: | Date: 2025-01-17 21:47:00